Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Trends in the molecular pathogenesis and clinical therapeutics of common neurodegenerative disorders Choonara YE; Pillay V; Du Toit LC; Modi G; Naidoo D; Ndesendo VMK; Sibambo SRInt J Mol Sci 2009[Jun]; 10 (6): 2510-2557The term neurodegenerative disorders, encompasses a variety of underlying conditions, sporadic and/or familial and are characterized by the persistent loss of neuronal subtypes. These disorders can disrupt molecular pathways, synapses, neuronal subpopulations and local circuits in specific brain regions, as well as higher-order neural networks. Abnormal network activities may result in a vicious cycle, further impairing the integrity and functions of neurons and synapses, for example, through aberrant excitation or inhibition. The most common neurodegenerative disorders are Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis and Huntington's disease. The molecular features of these disorders have been extensively researched and various unique neurotherapeutic interventions have been developed. However, there is an enormous coercion to integrate the existing knowledge in order to intensify the reliability with which neurodegenerative disorders can be diagnosed and treated. The objective of this review article is therefore to assimilate these disorders' in terms of their neuropathology, neurogenetics, etiology, trends in pharmacological treatment, clinical management, and the use of innovative neurotherapeutic interventions.|Alzheimer Disease/drug therapy/metabolism/pathology[MESH]|Amyloid beta-Peptides/metabolism[MESH]|Amyotrophic Lateral Sclerosis/drug therapy/metabolism/pathology[MESH]|Anticonvulsants/therapeutic use[MESH]|Antipsychotic Agents/therapeutic use[MESH]|Cholinergic Antagonists/therapeutic use[MESH]|Dopamine Agents/therapeutic use[MESH]|Humans[MESH]|Huntingtin Protein[MESH]|Huntington Disease/drug therapy/metabolism/pathology[MESH]|Nerve Tissue Proteins/metabolism[MESH]|Neurodegenerative Diseases/drug therapy/metabolism/*pathology[MESH]|Neurons/metabolism[MESH]|Parkinson Disease/drug therapy/metabolism/pathology[MESH]|alpha-Synuclein/metabolism[MESH]|tau Proteins/metabolism[MESH] |